We used a database of 4139 Taiwanese HCC patients to take a new approach (Network Phenotyping Strategy) to HCC sub-set identification. Individual parameters for liver function, complete blood count, portal vein thrombosis, AFP levels and clinical demographics of age, gender and hepatitis or alcohol consumption, were considered within the whole context of complete relationships, being networked with to all other parameter levels in the entire cohort. We identified 4 multi-parameter patterns for one tumor phenotype of patients and a separate 5 multi-parameter patterns to characterize another tumor phenotype of patterns.
Introduction
The prognosis and choice of treatments in patients who have hepatocellular carcinoma (HCC) has long been recognized to depend both on tumor factors as well as liver factors and was the basis for the first published classification scheme of Okuda (1) . This is because HCCs usually arise in a liver that has been chronically diseased (hepatitis or cirrhosis from hepatitis or other causes, or both) (2) (3) (4) (5) (6) . Many more complex classification and prognostication schemes have since been published, all of which take these 2 broad categories of factors into account, and patients can die either from their tumor growth or from their liver failure. However, there are additional layers of complexity that need to be taken into consideration. Thus, quite large HCCs can arise in surprisingly normal (non-cirrhotic liver). Furthermore, many small HCCs do not seem to grow further. Thus, some small HCCs stay small and others are precursors of larger HCCs. Since a patient can present at any random part of their HCC disease growth process, it is usually difficult to know at what point in their disease process they have been diagnosed. Given the suspicion that the diagnosis of HCC carries within it several or multiple sub-sets of disease, we recently used a tercile approach, to identify HCC sub-sets at the extreme wings of an HCC patient cohort that had been ordered according to tumor size and then trichotomized into tumor size terciles (7, 8) . We found that on the extreme terciles, there was a relationship between plasma platelet numbers and HCC size. This likely reflected that small HCCs arising in cirrhotic liver for which thrombocytopenia is a surrogate (9) with portal hypertension and a larger tumor size tercile without thrombocytopenia. However, it still left the central part of the tumor/disease continuum uncharacterized and unordered into sub-sets. Furthermore, we also showed a relationship between blood alpha-fetoprotein (AFP) levels, a marker of HCC growth, and blood total bilirubin levels, in a large part of the cohort (10) . This led support, as has evidence of others (11) (12) (13) , that HCC may not only arise and grow in a cirrhotic milieu, but may even depend on signals from that micro-environment for its growth and other biology. Given this unsatisfactory clinical HCC heterogeneity, it seems that 'one size fits all' doesn't work for individual prognostic factors, probably because of the absence of significant sub-subset patient separation. In addition, some parameters such as AFP can be elevated in either small or large HCCS. 4 We reasoned that attempts to extract new information cannot rely only on standard clinical data, but rather upon processing relationships between given data. In this report, we have taken a different approach to identify phenotypically different HCC patients groups. We first transformed the raw clinical screening data into a new form, considering in full the individual parameters within the whole context of complete relationships to all other parameter levels. After this transformation, individual parameters were not treated as single entries into the analysis, but were each considered as a parameter within the whole clinical context (liver function tests, Table I . The retrospective analysis was done under a university IRB-approved analysis of deidentified HCC patients.
Patient profiles.
We developed a Network Phenotyping strategy (NPS), a graph-theory based approach (10) , allowing personalized processing of complex phenotypes, with explicit consideration of functional parameter correlations and interdependencies. NPS was applied here to integrate the data of all 4139 HCC patients. There were no missing data in this data set. Individual patient profiles were created, in which each of 15 parameters was assessed in the context of all the other parameters for that same patient and processed by NPS approach. The technical details of NPS are presented in the Appendix. Here we summarize the concrete steps and their results:
Step 1. To reduce the complexity of the relationships that needs to be considered in the analysis, we considered correlations between blood liver function and hematological parameters. Out of 8 liver function parameters, we found 4 unique pairs that showed the most correlated and significant trends in their values. Some of these 4 were also strongly correlated in our previous work (10) . While the selection of the 4 parameter pairs with the strongest correlations amongst all >20,000 possible was done using just a maximal cut mathematical algorithm (14) , these 4 unique pairs were inter-related through established underlying functional processes: total blood bilirubin/prothrombin 6 time (a measure of liver function), SGOT/SGPT (a measure of liver inflammation) and AFP and blood platelet counts (reflections of tumor growth) (7).
Step 2. We continued by transforming the original patient data into a form of "levels".
This step unified the demographic (categorical) parameters with liver function (real value) parameters needed for consideration of their inter-relationships within directly clinically interpretable framework. Considering the established practice in HCC diagnostics (15, 16) , we determined 'high' and 'low' levels of each individual parameter Figure 1 . Set of four parameter pairs that have the highly correlated trends. One point represents a patient, in gray we show the upper tertile of patients identified with "high" levels of both parameters. In black are 2/3 of patients with "low" parameter levels. The boundary between the high and low levels is defined by the two threshold values indicated in every picture.
7 using a tercile-based dichotomization. For gender, reported alcoholism, evidence for hepatitis B and/or C and presence or absence of PVT the dichotomization was natural.
For the other parameters, we tested several alternatives (50%:50%, quartiles) but found that tercile dichotomization with 2/3 of patients with the lowest parameter levels designated as "Low" phenotype and 1/3 of patients with the highest parameter levels designated as "High" phenotype was optimal for further processing. For age the "old"
tercile was separated from the lower 2 "young" terciles by 55 years (17) . For the four significantly correlated parameter pairs, we used the two-thresholds that separate High from Low phenotypes, as shown in Fig. 1 . This resulted in clinically familiar value cutoffs, such as bilirubin of 1.5 mg/dl, AST 200 IU/l and ALT 105 IU/l.
Step 3. Using actual data for each patient, an individual clinical profile was created by connecting all the actual parameter high, low, + and -levels ( /l, AFP>29,000 ng/ml and presence of PVT. All these 4139 individual profiles were unified into a single schema (Appendix), that carries new information about co-occurrence frequencies of all parameter levels.
Step 4. We found a simpler structure in the networked HCC clinical data for this cohort.
The schema was completely decomposed into only 19 reference profiles C 1 -C 19 (Appendix). These reference clinical profiles had to have identical co-occurrence frequencies between all the parameter levels. This ensured the independency of the results on the parameter ordering in the clinical profile: re-arranging the sections in thus serve as idealized clinical statuses.
Step 5: The 4139 individual profiles were then compared in turn to each of the 19 reference profiles and the total number (0-10) of mismatches in the relationships they describe were recorded as differences d 1 -d 19 between the profiles.
Step 6. We next used logistic multiple regression (18) L-phenotype associated reference profiles (C 5 ,C 9 ) were male-related and C 12 ,C 18 were female-related. C 9 described younger and C 5 described older (>55 years) patients. For the female-associated profiles, C 12 described younger and C 18 older patients. Sphenotype associated reference profiles C 6 (young) and C 16 (older) were for female patients and C 1 (older), C 3 and C 8 (older) for male patients.
Trends between individual parameters and tumor mass in the S/L-sub-groups.
The networked characteristic profiles for the L-sub-group are more homogeneous than those in the S-sub-group. We examined whether there were significant differences in typical parameter values for the same tumor mass that might be found in each of the S/L-sub-groups.
We used a moving average filtering (Fig.3) where any tumor mass is characterized by the average of the clinical parameter values of 61 patients with the closest tumor masses (9) . We examined these trends in AFP (reflective of tumor growth) and platelet values and found increasing AFP and platelet counts with increasing tumor mass in Sand L-sub-group with different rates and magnitudes (Fig. 3a) . L-sub-group displayed a pattern of AFP/platelet level oscillations that were not observed in the S-sub-group.
Importantly, these L-phenotype unique oscillations were characteristic for the same tumor masses in both AFP and platelet trends (Fig. 3a) .
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The analysis of typical tumormass-related bilirubin level changes also showed differences in the 2 sub-groups (Fig. 3b) . The mechanisms underlying the oscillations did not seem to have an obvious explanation from clinical practice. However, possible clues came from analysis of the number of tumor nodules typical for the given tumor mass (Fig 3d) . We processed the data for tumor numbers in the same way as for other parameters and we found that (Fig. 3e) oscillations in tumor numbers corresponded to spikes in the parameter trends, especially seen for tumor mass <30.
Discussion
A database was constructed from a large number of newly diagnosed HCC patients, was used to characterize patient profiles, from which developed an algorithm that classified the patients into S-and L-subgroups. This characterization with significant difference in tumor masses was not obtained using raw data. Thus, the added information about trends and inter-dependencies of parameter values in a total parameter context was crucial for successful classification. The liver function and blood parameters were treated in 4 pairs, with unique significant correlations having a direct relationship to liver properties. These pairs were intuitively inter-related through established underlying functional processes: total blood bilirubin/prothrombin time (a measure of liver function), SGOT/SGPT (a measure of liver inflammation) and AFP Nevertheless, we have shown (Fig.3 ) that there were always 2-4 times higher odds for larger tumors in L than in S phenotype group. The differences in the tumor mass trends in the two sub-groups were significantly separated, showing the efficiency of our approach.
In the 2 phenotype groups, there was much greater homogeneity in the characteristic parameter patterns in L than in S. The rate of change for typical parameter values per unit change of tumor mass was always significantly higher for L-phenotype patients compared to S-phenotype patients, excepting the AST/ALT ratio, which was higher in S for tumor masses below 10 than for the same size tumors in L. One possible interpretation of these observations is that in S-phenotype patients, small tumors are associated with processes producing higher levels of the inflammatory markers, AST/ALT. We hypothesize that this might reflect the inter-connectedness of hepatic inflammation with tumor growth in the small tumors in this phenotype group. In Lsubgroup, the simplest explanation of parameter levels oscillations might be consideration of the number of tumor nodules that composed the tumor mass. A relationship between platelet numbers and tumor size was recently reported (7). Low platelets were interpreted to be a consequence of the portal hypertension that is 15 secondary to liver fibrosis. We found that most small HCCs in 2 large western cohorts occurred in the presence of thrombocytopenia, whereas the largest tumors occurred in patients with significantly higher, but normal platelet values.
By contrast, in the L-phenotype, the AST/ALT only really increased as the tumor masses became quite large. This may reflect the parenchymal liver damage that occurs when a large tumor develops and replaces underlying liver. In addition, in the L-phenotype, but not in S, several additional liver parameters showed oscillations in their typical values, as the tumor mass increased. We found a relationship between these oscillations and the numbers of tumors (Fig 3) . Given the lesser association of changes in inflammatory markers in the Lphenotype, we consider that other factors, likely tumor-related, may be more important on the growth of these tumors. Such factors likely include genetic drivers of HCC cell growth.
In the L-phenotype, the observed higher levels of various parameter contributions from multiple nodules to the total parameter levels could be additive.
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Step 1: In the first step, we considered correlations between clinical (blood liver function test and hematological) parameters. This has two important ramifications. First, in a formal, statistical sense any significant inter-correlation between individual parameter values represents a simplification of the analysis complexity (dimensionality reduction, we take into account that any two significantly correlated parameter pairs carry similar information). Second, any such significant correlation might indicate a functional relationship of the underlying processes. Therefore, building the NPS transformation of a study data, which explicitly considers such relationships, allows a simplified and more clinically intuitive processing of the extensive patient information such as in this study. Step 2. The next step in the construction of the NPS, was transformation of the original patient clinical data and their conversion into a common form of "levels". This step was necessary to be able to unify the demographic (categorical) parameters with liver function (real value) parameters and allow for consideration of their inter-relationships within a common, explicit, quantitative but still directly clinically interpretable framework.
Considering the established practice in HCC diagnostic evaluation, we found that a common approach to determine levels of each individual parameter can be tercilebased dichotomization. For gender, reported alcoholism, evidence for hepatitis B and C and presence or absence of portal vein thrombosis (PVT) the dichotomization was natural. For the rest of parameters, we tested several alternative dichotomizations (50%:50%, quartiles) but found that tercile dichotomization with 2/3 of patients with the lowest parameter levels designated as "Low" phenotype and 1/3 of patients with the highest parameter levels designated as "High" phenotype was optimal for further processing (see below). Also, the resulting thresholds, splitting the 4139 patients into 2759 subjects in "low" sub-group and 1380 patients into a "high" sub-group were comparable with values used in established HCC classification schemes. For age the "old" tercile was separated from the lower 2 "young" terciles by 55 years. For the four parameter pairs that were found as significantly correlated in step 1, we used twothreshold method, as shown in Fig. 1 For these pairs, the upper tercile is defined by the 2 individual thresholds of the individual parameters that separate High from Low values. This resulted in clinically familiar value cutoffs, such as bilirubin of 1.5 mg/dl, AST 200 IU/l and ALT 105 IU/l.
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Another advantage of this approach, seen in text Fig. 1 , is that the outliers from these trends, with the very high values, do not impact significantly the values of the tercilebased thresholds. We have also shown that inclusion or exclusion of these outliers in all trends, both individually and simultaneously from analysis did not change the final NPS representation of patient's data and, more importantly, did not affect the essential steps in further processing. Thus, our NPS approach is very robust and optimally sensitive to coherent as well as insensitive to stochastic components of raw HCC data.
Step 3. Using actual data for each patient, an individual clinical profile was created by connecting the actual parameter high, low, + and -levels for that individual (text Fig. 2 ).
We then created an individual patient profile for each of the 4139 patients. All these individual profiles were then unified into a single schema. In this unified cohort of profiles, each line in each patient's profile, representing the relationship between the actual parameter levels in individual profiles is counted as a contribution of that specific individual parameter relationship to collective NPS schema, In this way, we incorporated into the study schema the new information about frequencies of co-occurrences of all respective parameter levels in a simple intuitive way. The co-occurrence frequencies are represented graphically by the thickness of the line connections between levels of each parameter (Fig. S1) . Thus, as an illustrative example, we can directly infer from Fig. S1 (following the dotted edges) that the majority of the cohort has low platelets, low AFP levels and no portal vein thrombus and also have more males than females. The full information of text Table 1 is represented by this schema. The next step that we took ensured that the data transformation was not dependent on the order in which the parameters inter-connected in this unified profile.
Step 4. Using a greedy algorithm (extracting sequentially the co-occurrence relationship profiles that has the highest frequency in the dataset and repeating this process until there was no relationship left), the unified profile was decomposed into 19 reference Figure S2 . Full decomposition of the single schema of all networked context relationships in the study data into reference clinical profiles C1-C1. Numbers in rectangles are multiplicities of every reference clinical profile in the decomposition. By dividing these multiplicities by 4139, the total number of patients in the study, we obtain for each reference profile the relative frequencies of its occurrence in the HCC study.
profiles, in such a way that all co-occurrence frequencies between all the parameter levels in a reference profile were identical. This generated unique, data-determined reference clinical profiles with equal frequencies of co-occurrences of all parameter pair levels -see Step 5. We next used logistic multiple regression, using 19 distances of the individual patient's clinical profiles from each of the 19 reference clinical profiles as independent variables, to predict whether an individual had a tumor mass larger or smaller than 5.5. For more detailed analysis of the tumor mass differences in the two different phenotype groups, we used the R-implementation of Kaplan-Meier analysis in the "survival"
package. The motivation of this approach was that the large number of patients in our data set (and in the two S-and L-phenotype sub-categories) allowed us to consider their tumor masses as snapshots of the growth of an idealized tumor in different clinical contexts. Thus, the respective tumor masses in the two clinical phenotype subcategories were considered as independent variables in KM processing. In this model, no censoring is required. Results indicated that the odds to find the same tumor masses in the S-and L-phenotype groups are significantly different with separation close to 10x of the 95% confidence intervals.
